Redeye endorses the directed share issue of SEK 159m, adding substantial length to Episurf Medical's financial runway with Ilija Batljan stepping in as a new large shareholder. The funds should carry operations into 2025 and, therefore, wipes out any medium-term financial concerns investors might have while also demonstrating the company’s capabilities of securing funds in a confidence-inspiring way.